Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence-Reference-Cited by-同舟云学术

Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence

Published:2019-07-19 Issue:11 Volume:35 Page:1911-1923
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Gemayel Nathalie C.¹^ORCID,Rizzello Eugenio²,Atanasov Petar¹,Wirth Daniel³^ORCID,Borsi Andras⁴^ORCID

Affiliation:

1. Health Economics & Market Access (HEMA), Amaris Consulting Ltd, Barcelona, Spain;

2. Health Economics & Market Access (HEMA), Amaris Consulting Ltd, London, UK;

3. Market Access, Janssen-Cilag GmbH, Neuss, Germany;

4. Market Access, Janssen EMEA, High Wycombe, UK

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://tandfonline.com/doi/pdf/10.1080/03007995.2019.1631058

Reference58 articles.

1. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future

2. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

3. American Gastroenterological Association (AGA). Clinical care pathway of ulcerative colitis patients [Internet]. [cited 2018 Sep]. Available from: http://campaigns.gastro.org/algorithms/UlcerativeColitis/

4. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis;Crohn's & Colitis 360;2024-04-01

2. Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data;Clinical Gastroenterology and Hepatology;2023-12

3. Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study;Crohn's & Colitis 360;2023-10-01

4. Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe;Current Medical Research and Opinion;2023-08-28

5. Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States;Crohn's & Colitis 360;2023-07-01